Abobaker Magdi, Govender Mershen, Choonara Yahya E
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Pharmaceutics. 2025 Jun 30;17(7):860. doi: 10.3390/pharmaceutics17070860.
: Skin cancer remains a significant global health issue, driving the development of new treatment strategies to improve clinical outcomes and prevent recurrence. Traditional monotherapies often face obstacles such as bioactive resistance, prompting interest in combination therapies that enhance efficacy, while minimizing side effects. This study investigated the use of a co-nanoparticle approach of iron oxide nanoparticles (NPs) surface-functionalized with curcumin (Cur-FeONPs) delivered with prolonged-release interferon alpha (IFNα)-loaded PLGA NPs (IFNα-PLGANPs) for the synergistic treatment of malignant melanoma tested in A375 cells. : Extensive in vitro characterization studies of the Cur-FeONPs and IFNα-PLGANPs were performed, including zeta-size profiling, morphological studies, and structural validation, in addition to cytotoxicity assessments on A375 melanoma and NIH-3T3 fibroblast cells. : The Cur-FeONP and IFNα-PLGANPs synthesis processes yielded NPs with an average size of 111.0 nm and 97.0 nm, respectively. Morphological and structural validation studies determined the successful synthesis of the nanoparticulate systems, with cell viability analyses displaying significant cytotoxicity against A375 melanoma cells for the combination treatment, when compared to the individual platforms, with a minimal effect on NIH-3T3 fibroblast cells. : The results of this study present a promising synergistic approach for enhanced anticancer activity in A375 melanoma skin cancer cells, providing a potential platform for future preclinical and clinical studies.
皮肤癌仍然是一个重大的全球健康问题，推动了新治疗策略的发展，以改善临床结果并预防复发。传统的单一疗法常常面临诸如生物活性抗性等障碍，这引发了人们对联合疗法的兴趣，联合疗法可提高疗效，同时将副作用降至最低。本研究调查了一种共纳米颗粒方法的应用，即使用姜黄素表面功能化的氧化铁纳米颗粒（Cur-FeONPs）与负载长效干扰素α（IFNα）的聚乳酸-羟基乙酸共聚物纳米颗粒（IFNα-PLGANPs）联合，用于在A375细胞中测试的恶性黑色素瘤的协同治疗。对Cur-FeONPs和IFNα-PLGANPs进行了广泛的体外表征研究，包括zeta尺寸分析、形态学研究和结构验证，此外还对A375黑色素瘤细胞和NIH-3T3成纤维细胞进行了细胞毒性评估。Cur-FeONP和IFNα-PLGANPs的合成过程分别产生了平均尺寸为111.0 nm和97.0 nm的纳米颗粒。形态学和结构验证研究确定了纳米颗粒系统的成功合成，细胞活力分析显示，与单独的平台相比，联合治疗对A375黑色素瘤细胞具有显著的细胞毒性，而对NIH-3T3成纤维细胞的影响最小。本研究结果为增强A375黑色素瘤皮肤癌细胞的抗癌活性提供了一种有前景的协同方法，为未来的临床前和临床研究提供了一个潜在的平台。
